Alterity Therapeutics Ltd ADR (ATHE) Stock Price, Quote & News

Company Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202...

Industry: Biotechnology

Sector: Healthcare

Phone: 61 3 9349 4906

Fax: 61 3 9349 4906

Website: alteritytherapeutics.com

Address:

350 Collins Street, Suite 4 Level 14, Melbourne, Australia

stckmuncher Feb. 4 at 4:19 PM

$ATHE Nice movement on relatively low volume!!! ✅

0 · Reply

stckmuncher Feb. 3 at 4:34 PM

$ATHE Big money coming!

1 · Reply

RocketMan88 Feb. 3 at 3:48 PM

$ATHE $5 floor here we come!

0 · Reply

GA09 Jan. 30 at 1:44 AM

$ATHE This is extremely positive along with the rest of the update. They are ready for the EO2 meeting with the FDA and are already having partnering discussions with a number of pharmaceutical companies. From my experience, their chance of being acquired increases once they are aligned on Phase 3 trial with the FDA.

0 · Reply

AshleySchaeffer_BMW Jan. 30 at 1:16 AM

$ATHE looking strong lads https://alteritytx.com/announcements/7333308

1 · Reply

anastasia_beaverhausen1 Jan. 29 at 11:49 PM

$ATHE new PR https://alteritytx.com/announcements/7333308

0 · Reply

stckmuncher Jan. 29 at 2:32 AM

$ATHE WE OUT HERE!

0 · Reply

stckmuncher Jan. 29 at 2:30 AM

$ATHE My buddy has 10k shares!

0 · Reply

stckmuncher Jan. 29 at 2:29 AM

$ATHE I LOVE THIS STOCK :)

0 · Reply

stckmuncher Jan. 29 at 2:29 AM

$ATHE UP UP UP AND AWAY!!!!

0 · Reply

Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update

Nov 12, 2025, 7:25 AM EST - 3 months ago

Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference

Oct 31, 2025, 7:25 AM EDT - 3 months ago

Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report

Oct 9, 2025, 7:25 AM EDT - 4 months ago

Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson's Disease and Movement Disorders

Oct 2, 2025, 7:35 AM EDT - 4 months ago

Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders

Sep 8, 2025, 7:35 AM EDT - 5 months ago

Alterity Therapeutics Raises A$20.0 million in Strategic Placement

Sep 2, 2025, 7:25 AM EDT - 5 months ago

Alterity Therapeutics to Present at the Biotech Showcase

Jul 30, 2025, 7:25 AM EDT - 6 months ago

Appendix 4C – Q4 FY25 Quarterly Cash Flow Report

Jul 28, 2025, 7:25 AM EDT - 6 months ago

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy

Jul 24, 2025, 7:25 AM EDT - 6 months ago

Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study

Jun 23, 2025, 7:25 AM EDT - 8 months ago

Alterity Therapeutics to Provide Corporate Update in Fireside Chat

May 12, 2025, 7:35 AM EDT - 9 months ago

Alterity Therapeutics Prominently Featured at the International MSA Congress

May 7, 2025, 8:16 AM EDT - 9 months ago

Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress

May 5, 2025, 7:35 AM EDT - 9 months ago

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

Apr 30, 2025, 7:35 AM EDT - 10 months ago

Appendix 4C – Q3 FY25 Quarterly Cash Flow Report

Apr 28, 2025, 7:35 AM EDT - 10 months ago

Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium

Apr 10, 2025, 7:35 AM EDT - 10 months ago

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

Mar 27, 2025, 7:25 AM EDT - 11 months ago

Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

Feb 10, 2025, 7:25 AM EST - 1 year ago

Alterity Therapeutics Raises A$40.0 million in Placement

Jan 30, 2025, 7:35 AM EST - 1 year ago

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

Jan 24, 2025, 7:35 AM EST - 1 year ago

Appendix 4C – Q2 FY25 Quarterly Cash Flow Report

Jan 9, 2025, 7:25 AM EST - 1 year ago

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

Dec 4, 2024, 7:35 AM EST - 1 year ago

Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy

Nov 19, 2024, 7:25 AM EST - 1 year ago

Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary

Nov 12, 2024, 7:35 AM EST - 1 year ago

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

Nov 6, 2024, 7:35 AM EST - 1 year ago

Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

Oct 31, 2024, 7:35 AM EDT - 1 year ago

Appendix 4C – Q1 FY25 Quarterly Cash Flow Report

Oct 14, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024

Oct 11, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting

Oct 2, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

Sep 30, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer

Sep 23, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

Jul 31, 2024, 7:35 AM EDT - 1 year ago

Appendix 4C – Q4 FY24 Quarterly Cash Flow Report

Jul 24, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics to Present at MST Financial Webinar

Jul 17, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Jul 17, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Jun 12, 2024, 7:22 PM EDT - 1 year ago

Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences' Webinar

May 29, 2024, 7:21 PM EDT - 1 year ago

Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study

May 8, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

Apr 30, 2024, 7:25 AM EDT - 1 year ago

Appendix 4C – Q3 FY24 Quarterly Cash Flow Report

Apr 29, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich's Ataxia

Apr 17, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting

Apr 10, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024

Mar 26, 2024, 10:25 AM EDT - 2 years ago

Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund

Feb 20, 2024, 10:25 AM EST - 2 years ago

Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting

Feb 6, 2024, 7:25 AM EST - 2 years ago

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

Jan 29, 2024, 7:24 AM EST - 2 years ago

Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week

Dec 21, 2023, 12:30 AM EST - 2 years ago

Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer

Dec 4, 2023, 4:35 PM EST - 2 years ago

Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress

Dec 4, 2023, 7:25 AM EST - 2 years ago

Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease

stckmuncher Feb. 4 at 4:19 PM

$ATHE Nice movement on relatively low volume!!! ✅

0 · Reply

stckmuncher Feb. 3 at 4:34 PM

$ATHE Big money coming!

1 · Reply

RocketMan88 Feb. 3 at 3:48 PM

$ATHE $5 floor here we come!

0 · Reply

GA09 Jan. 30 at 1:44 AM

0 · Reply

AshleySchaeffer_BMW Jan. 30 at 1:16 AM

$ATHE looking strong lads https://alteritytx.com/announcements/7333308

1 · Reply

anastasia_beaverhausen1 Jan. 29 at 11:49 PM

$ATHE new PR https://alteritytx.com/announcements/7333308

0 · Reply

stckmuncher Jan. 29 at 2:32 AM

$ATHE WE OUT HERE!

0 · Reply

stckmuncher Jan. 29 at 2:30 AM

$ATHE My buddy has 10k shares!

0 · Reply

stckmuncher Jan. 29 at 2:29 AM

$ATHE I LOVE THIS STOCK :)

0 · Reply

stckmuncher Jan. 29 at 2:29 AM

$ATHE UP UP UP AND AWAY!!!!

0 · Reply

stckmuncher Jan. 29 at 2:29 AM

$ATHE WE GO UP!!!!!!

0 · Reply

stckmuncher Jan. 29 at 2:16 AM

$ATHE BUILD THE HYPE BRO!

0 · Reply

stckmuncher Jan. 29 at 2:16 AM

$ATHE Where my bitches at?

0 · Reply

stckmuncher Jan. 27 at 2:21 PM

$ATHE You can make a difference today.

0 · Reply

stckmuncher Jan. 27 at 2:20 PM

$ATHE We do not back down. This stock goes to $12+

0 · Reply

stckmuncher Jan. 27 at 2:20 PM

$ATHE It’s on we the people to get the message out!

0 · Reply

RocketMan88 Jan. 26 at 9:40 PM

$ATHE all that excitement today only for my rocket to prematurely eject its fuel at close and go back to even.

0 · Reply

FITTEST_RETAIL_TRADER Jan. 26 at 3:37 PM

$ATHE READY TO TAKE OFFFFFFF

0 · Reply

Dingo2 Jan. 26 at 3:16 PM

$ATHE interesting seeing some volume incoming!!

0 · Reply

motherlandreturns Jan. 26 at 3:01 AM

$ATHE I hope it is a good week this week 🎉 could use it since it is so cold right now my ASSets are frozen 🥶🤣

0 · Reply

tommy_john Jan. 25 at 3:57 PM

$ATHE 2026 is a huge year here!!! The high was $10 off hours last year. We should eat that up with news

1 · Reply

Dingo2 Jan. 21 at 2:35 PM

$ATHE LOL - Schwab is becoming a pain in the ars. Have to call in buys now for ATHE among others. Might be time to move the $$ elsewhere for easier ins and outs

1 · Reply

Market Cap	28.11M
Revenue (ttm)	0.00
Net Income (ttm)	-7.87M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	4,065
Avg Vol	14,636
Day's Range	N/A - N/A
Shares Out	8.87M
Stochastic %K	0%
Beta	0.06
Analysts	Strong Sell
Price Target	$11.00